Sarda Proteins revises FY26 audited results; PAT jumps to Rs 45.44 lakh

Sarda Proteins resubmitted FY26 audited results with corrections to interest income booking and reclassification of share warrants as equity. Company says changes are clerical with no material impact. Revenue from operations fell to Rs 1,525.85 lakh from Rs 2,419.10 lakh. However, PAT rose to Rs 45.44 lakh vs Rs 0.50 lakh, boosted by interest income. Total equity surged to Rs 8,620.74 lakh from Rs 237.80 lakh on share warrant conversion. Operating cash flow was deeply negative at Rs 7,618.40 lakh.